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To evaluate systemic adverse events after screening for retinopathy of prematurity (ROP)
performed with mydriatic.
Methods
This was a retrospective case series study. Medical records of consecutive patients who
underwent screening for ROP with 0.5% phenylephrine and 0.5% tropicamide eyedrops
were retrospectively reviewed. The score of abdominal distention (0–5), volume of milk
sucked and volume of stool, along with systemic details (pulse and respiration rates, blood
pressure and number of periods of apnea) were collected at 1 week and 1 day before ROP
examination, and at 1 day after examination. Results were compared between the days
before and after examination. Correlation between body weight at the time of examination
and the score of abdominal distention was examined. The numbers of infants with abdomi-
nal and/or systemic adverse events were compared between pre- and post-examination
periods.
Results
Eighty-six infants met the inclusion criteria. The score of abdominal distention increased
from 2.0 at 1 day before examination to 2.3 at 1 day after examination (p = 0.005), and the
number of infants who had worsened abdominal distension increased after examination
(p = 0.01). Infants with lower body weight had a higher score of abdominal distention
(p < 0.0001, r = −0.57). The number of infants with reduced milk consumption increased
after examination (p = 0.0001), as did the number of infants with decreased pulse rate
(p = 0.0008).
Conclusions
Screening for ROP with mydriatic may have adverse effects on systemic conditions. Infants
should be carefully monitored after ROP screening with mydriatic.
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Introduction
Retinopathy of prematurity (ROP) is a leading cause of childhood blindness world-wide [1].
Screening preterm infants at risk of ROP requires serial funduscopic examinations using myd-
riatic eyedrops; 0.5–1.0% tropicamide and/or 0.5–10% phenylephrine and/or 0.2–1.0% cyclo-
pentolate eyedrops. Some complications from mydriatic eyedrops have been reported in
preterm infants. Systemic absorption of mydriatic eyedrops has been associated with cardio-
vascular, respiration and gastrointestinal adverse effects [2,3]. ROP screening using cyclopen-
tolate may be associated with increased gastric residuals and delayed gastric emptying [4,5]. In
Japan, 0.5% phenylephrine and 0.5% tropicamide eyedrops are commonly used for ROP
screening. There have been reports about systemic adverse events from other mydriatics or
from different doses of combined phenylephrine and tropicamide eyedrops other than case
reports.[4–6]. However, to the best of our knowledge, there is one report regarding abdominal
adverse effects after ROP screening with 0.5% phenylephrine and 0.5% tropicamide eyedrops.
This previous report evaluated necrotizing enterocolitis and gastric residual as abdominal
adverse effects [7]. In this report, we evaluated score of abdominal distention, volume of milk
sucked, volume of stool as abdominal distention, and pulse rate, respiration rate, blood pres-
sure and number of episodes of apnea as systemic adverse events from ROP screening with
0.5% phenylephrine and 0.5% tropicamide eyedrops between before and after ROP screening.
Methods
This study protocol was approved by the Institutional Review Board (IRB)/Ethics Committee
Shiga University of Medical Science (Otsu, Japan). For this type of retrospective study, an opt-
out consent process was used at our institution. All data were fully anonymized before we
accessed them. Patients’ medical records were accessed from July 2019 to December 2020.
This study adhered to the tenets of the Declaration of Helsinki. Medical records of consecutive
preterm infants who were screened for ROP between June 2016 and March 2018 at the Shiga
University of Medical Science Hospital Neonatal Intensive Care Unit (NICU) were retrospec-
tively reviewed. The ROP screening was performed following the guidelines proposed by the
American Academy of Ophthalmology, and the Association for Pediatric Ophthalmology and
Strabismus [8], with some modifications. ROP screening was performed after instilling 0.5%
phenylephrine and 0.5% tropicamide eyedrops 3 times at a 15-minute interval. For infants
with abdominal trouble before ROP screening, we used 0.25% phenylephrine and 0.25% tropi-
camide eyedrops by diluting the eyedrops. Infants whose ROP screening was performed with
the lower-dose eyedrops were excluded from the present study. Gestational age, birth weight,
gender and time of first ophthalmic examination were collected from medical charts. Score of
abdominal distention (0–5), volume of milk sucked, volume of stool, and pulse rate, respira-
tion rate, blood pressure and number of episodes of apnea (cessation of respiration for�20 s,
or cessation of respiration of any duration accompanied by bradycardia (heart rate<100/min)
and/or cyanosis was defined as an episode) were collected from the medical records of patients
at 1 week and 1 day before ROP examination, and 1 day after examination. We defined the
period from 1 week to 1 day before as the “period before examination” and the period from 1
day before to 1 day after as the “period after examination.” We also defined 1 day before exam-
ination as the “baseline”. The abdominal-distention score was defined as follows, and was eval-
uated by nurses in the NICU: 0 = no abdominal distension; 1 = slight abdominal distension;
2 = abdominal distension that was mild but soft; 3 = abdominal distension that was moderate
but soft; 4 = abdominal distension that was moderate and slightly hard; and 5 = severe abdomi-
nal distension that was hard. Mean results were compared for 1 week before, 1 day before and
1 day after examination. However, analysis of only the mean data might mask the effects on
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individual infants. Therefore, we also analyzed the means of individual measurements and the
numbers of infants who changed between before versus after examination.
Correlation between the score of abdominal distention and body weight at screening was
performed.
Statistical analyses were performed using GraphPad Prism 6 software (GraphPad Software,
Inc., La Jolla, CA, USA). The results were expressed as the mean ± standard deviation (SD) for
continuous variables and as proportions (%) for categorical variables. The Wilcoxon test was
used for comparisons of changes between 1 week before, baseline and 1 day after examination.
Spearman correlation coefficients were assessed to determine the relationships between body
weight at ROP screening and abdominal-distention score. McNemar’s test was used to com-
pare the number of infants who had a change in abdominal and systemic adverse effects
between the period before examination and the period after examination. P-values < 0.05
were considered significant.
Results
Eighty-nine babies were screened for ROP during the period under investigation. All data
are provided in S1 File. Pupil dilation was performed with 0.5% phenylephrine and 0.5% tro-
picamide eyedrops in 86 patients (96.6%). The eyedrops were diluted by half in the other 3
patients, who had abdominal trouble before ROP screening (3.4%). Eighty-six infants who
underwent screening of ROP in our hospital met the inclusion/exclusion criteria and were
included in this study. Forty-two patients were female (49%). Gestational ages ranged from
24–35.1 weeks post-menstrual age (PMA) (mean: 32 weeks), and weights ranged from 654–
2710 g (mean ± SD: 1606 ± 438.7 g) at birth. PMAs at time of ROP screening ranged from
29.7–39.3 weeks (mean: 35.3 weeks), and body weight ranged from 856–2674 g (mean ± SD:
1871 ± 442.4 g).
Abdominal distention
The abdominal-distention scores decreased significantly from 1 week to 1 day before ROP
examination. The abdominal-distention scores then increased significantly from 2.0 at baseline
to 2.3 at 1 day after examination (p = 0.005 for both comparisons, paired-t tests with Bonfer-
roni correction, see Fig 1).
Compared with their scores at 1 week before examination, the scores had worsened in 7
patients (8.1%) at 1 day before examination. However, compared with their baseline score, the
score worsened in 21 patients (24.4%) at 1 day after examination. Compared with the period
before examination (from 1 week before examination to baseline), there was a significant
increase in the number of infants whose abdominal score worsened during the period after
examination (from baseline to 1 day after examination) (p = 0.01, McNemar’s test).
Infants with lower body weight at the time of their ROP screening had higher scores of
abdominal distention at that time (p< 0.0001, r = −0.57 Spearman rank correlation coeffi-
cient, see Fig 2).
Other abdominal adverse events
Details regarding the volumes of milk consumed were collected for the 86 neonates. The mean
amount of milk sucked per infant per day increased significantly from 284.5 ± 89.4 ml at 1 day
before examination to 303.4 ± 96.1 ml at 1 day after examination (p< 0.0001, paired-t test,
Fig 3).
However, compared with the amount of milk sucked at 1 week before examination, the
amount decreased in 6 patients (6.9%) at 1 day before examination. Compared with the
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amount of milk sucked at 1 day before examination, the volume decreased in 20 patients
(23%) at 1 day after examination. Compared with the period before examination (from 1 week
before examination to baseline), there was a significant increase in the number of infants who
decreased the amount of milk that they sucked during the period after examination (from
baseline to 1 day after examination) (p = 0.0001, McNemar’s test).
The measured volumes of stool were collected from the records of 66 of the neonatal
infants. The volume of stool increased significantly from 24.5 ± 11.0 g at 1 week before exami-
nation to 29.8 ± 11.3 g at 1 day before screening (p = 0.0082, paired-t test, Fig 4), but the vol-
ume of stool did not significantly increase from 29.8 ± 11.3 g at 1 day before screening to
30.1 ± 12.7 g at 1 day after examination (p> 0.05, paired-t test, Fig 4).
Compared with the period before examination (from 1 week before examination to base-
line), there was no significant change in the number of infants who decreased the volume of
Fig 1. The scores of abdominal distention from 1 week before examination to 1 day after screening for
retinopathy of prematurity. Low scores of abdominal distention represent less abdominal distention. �Statistical
difference (p < 0.05, paired-t tests with Bonferroni correction).
https://doi.org/10.1371/journal.pone.0256878.g001
Fig 2. Correlation between body weights at retinopathy of prematurity (ROP) examinations and the scores of
abdominal distention.
https://doi.org/10.1371/journal.pone.0256878.g002
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stool during the period after examination (from baseline to 1 day after examination) (p> 0.05,
McNemar’s test). None of the neonatal infants developed ileus during the examination period.
Systemic vital data
Pulse rates increased significantly from 148 ± 23.8 beats per minute (bpm) at 1 week before
examination to 154 ± 12.9 bpm at 1 day before examination (p = 0.02, paired-t test). However,
pulse rates did not increase from baseline to 1 day after examination (Fig 5).
Compared with the pulse rate at 1 week before examination, the rate had decreased in 33
patients (38.8%) and increased in 52 patients at 1 day before examination. Compared with
rates at 1 day before examination, the rate decreased in 47 patients (56.4%) and increased in 38
patients at 1 day after examination. Compared with the period before examination (from 1
Fig 3. The volume of milk sucked, per infant per day, from 1 week before examination to 1 day after examination.
�Statistical difference (p < 0.05, paired-t tests with Bonferroni correction).
https://doi.org/10.1371/journal.pone.0256878.g003
Fig 4. The daily stool volumes measured from 1 week before examination to 1 day after examination. �Statistical
difference (p < 0.05, paired-t tests with Bonferroni correction).
https://doi.org/10.1371/journal.pone.0256878.g004
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week before examination to baseline), there was a significant increase in the number of infants
whose pulse rate decreased during the period after examination (from baseline to 1 day after
examination) (p = 0.0008, McNemar’s test).
Respiration rate, blood pressure (systolic and diastolic) and episodes of apnea did not
change significantly through the study period (p> 0.07, paired-t tests, Fig 6).
Fig 5. Pulse rates from 1 week before examination to 1 day after examination. �Statistical difference (p< 0.05,
paired-t tests with Bonferroni correction).
https://doi.org/10.1371/journal.pone.0256878.g005
Fig 6. Systolic and diastolic blood pressure, number of periods of apnea and respiration rates from 1 week before
examination to 1 day after examination.
https://doi.org/10.1371/journal.pone.0256878.g006
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Discussion
In the current study, the abdominal-distention scores significantly increased and the number
of neonatal infants who consumed a reduced amount of milk increased after ROP screening
with 0.5% phenylephrine and 0.5% tropicamide eyedrops. To the best of our knowledge, our
study is the first to evaluate abdominal adverse events (abdominal-distension scores, volume
of milk sucked and the volume of stool) after ROP screening with this combination of eye-
drops between before and after ROP screening. In Japan, 0.5% phenylephrine and 0.5%
tropicamide eyedrops are commonly used for ROP screening. Jiang et al. reported that ROP
screening with 0.5% phenylephrine and 0.5% tropicamide was associated with residual gastric
contents and necrotizing enterocolitis using a different evaluation item from the current study
[7]. However, there are some reports in which other mydriatics, or different doses of phenyl-
ephrine-and-tropicamide, were used.
In the previous reports with different doses of phenylephrine-and-tropicamide, abdominal
adverse effects have been reported. Degirmencioglu et al. reported a case of an infant with very
low birth weight who developed significant abdominal symptoms (mimicking ileus), with dis-
continuation of oral feeding, after ocular instillation of 2.5% phenylephrine and 0.5% tropica-
mide eyedrops for routine examination of ROP [9]. In this previous report, the concentration
of phenylephrine was higher than that in the current study. Even relatively thin concentrations
of 0.5% phenylephrine and 0.5% tropicamide eyedrops may have adverse effects on abdominal
adverse effects.
In the previous reports with other mydriatics, abdominal adverse effects have been
reported. A 2-month-old girl had episodes of apnea, vomiting and distension after a screening
for ROP with cyclopentolate 0.5% and phenylephrine 2.5% [10]. Bonthala et al. reported that
ocular instillation of 0.2% cyclopentolate and 1.0% phenylephrine eyedrops inhibited duodenal
motility and delayed gastric emptying in 11 infants; this might have been caused by a reduction
in peristaltic movement of the gastrointestinal tract [5]. ROP screening using cyclopentolate,
therefore, might be associated with increased gastric residuals and cyclopentolate was detected
in the blood of infants, whereas phenylephrine was not detected in the blood [4]. In another
report, the incidence of gastric residual increased after ROP screening with another type and/
or dose of mydriatic [11]. In these reports, cyclopentolate was used for ROP screening; there-
fore, it may cause abdominal adverse effects.
In the present study, neonatal infants with lower body weight at the ROP screening had
higher scores of abdominal distention. However, because those infants also had higher scores
of abdominal distention before ROP screening, we should be careful about attributing the
abdominal adverse effects to the mydriatic (alone). Jiang et al. reported that the incidence of gas-
tric residuals increased after ROP screening in infants with postconceptional age< 31 weeks [7].
Gronlund et al. reported that, in neonatal lambs, the sympathetic nervous system is a major regu-
lator of cardiovascular interactions and that the autonomic nerves are immature [11]. The imma-
turity of autonomic nerves in neonatal infants might contribute to abdominal adverse effects.
In the current study, compared with the period before examination, there was a significant
increase in the number of infants with decreased pulse rate during the period after examina-
tion. In some previous reports, pulse rate did not significantly change after ROP screening
[5,12–15]. However, Khoo et al. reported that pulse rates decelerated below the baseline values
after ROP screening [16]. Rosales et al. stated that stress and pain during ophthalmic examina-
tions are known to precipitate apnea and bradycardia [17]. Stress and pain during ophthalmic
examination may affect pulse rate until at least 1 day after ROP screening.
In the current study, the volume of stool, respiration rate, blood pressure and number of
episodes of apnea did not change significantly after ROP screening (p> 0.05 paired-t tests). In
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a previous report, a significant elevation in systolic blood pressure was observed in 8 of 10
infants [17]. In a different study, percutaneous oxygen saturation and pulse rate changed sig-
nificantly from baseline values following ROP screening with 2.5% phenylephrine and 0.5%
tropicamide eyedrops. There were no significant changes in blood pressure, temperature, or
respiration rate [18]. Jiang et al. reported significant increases in blood pressure after adminis-
tration of phenylephrine 0.5% and tropicamide 0.5% [7]. Lees et al. reported that blood pres-
sure was significantly elevated but pulse rate was unchanged after ROP screening with 2.5%
phenylephrine and 0.5% tropicamide eyedrops [13]. Isenberg et al. also reported significantly
elevated blood pressures after ROP screening with 2.5% phenylephrine and 0.5% tropicamide
eyedrops [12], but blood pressure did not change after ROP screening with the same types and
doses of eyedrops in a study by Bolt et al. [19]. Thus, there are still controversies about changes
in pulse rate, respiration rate, blood pressure and periods of apnea, which may be due to differ-
ences in the kind and/or dose of mydriatics used and/or the time of ophthalmic examination.
The current study had some limitations in that it was a retrospective study, with a small
sample size and without control cases. Because we evaluated data only up to 1 day after screen-
ing, any long-term effects are unknown. Finally, the cause of the abdominal adverse effects was
unclear and not only the mydriatics, but also the ophthalmic examinations themselves, might
contribute to the changes seen.
In conclusion, screening for ROP with 0.5% phenylephrine and 0.5% tropicamide eyedrops
may have adverse effects on systemic conditions such as abdominal distention, milk consump-
tion and pulse rate. Careful observation for abdominal conditions should be performed after
ROP screening with mydriatic.
Supporting information
S1 File. Data set for analysis.
(XLSX)
Acknowledgments
We thank Claire Barnes, PhD, from Edanz Group (www.edanzediting.com/ac) for editing a
draft of this manuscript.
Ethics approval. All procedures performed in this study involving human participants were
in accordance with the ethical standards of the institutional and/or national research committee
and with the 1964 Helsinki declaration and its later amendments or comparable ethical stan-
dards. The study was approved by the Institutional Review Board (IRB)/Ethics Committee
Shiga University of Medical Science (Otsu, Japan). All data were fully anonymized before we
accessed them. Patients’ medical records were accessed from July 2019 to December 2020.
Consent to participate. For this type of study, formal consent was not required.
Author Contributions
Conceptualization: Shumpei Obata, Taku Imamura, Masashi Kakinoki, Takahide Yanagi,
Yoshihiro Maruo, Masahito Ohji.
Data curation: Shumpei Obata, Taku Imamura, Masashi Kakinoki.
Formal analysis: Shumpei Obata, Taku Imamura, Masahito Ohji.
Funding acquisition: Masahito Ohji.
Investigation: Shumpei Obata, Masashi Kakinoki, Takahide Yanagi, Masahito Ohji.
PLOS ONE Adverse events after ROP screening
PLOS ONE | https://doi.org/10.1371/journal.pone.0256878 September 9, 2021 8 / 10
Methodology: Shumpei Obata, Taku Imamura, Takahide Yanagi, Yoshihiro Maruo, Masahito
Ohji.
Project administration: Masahito Ohji.
Supervision: Yoshihiro Maruo, Masahito Ohji.
Writing – original draft: Shumpei Obata.
Writing – review & editing: Taku Imamura, Masashi Kakinoki, Takahide Yanagi, Yoshihiro
Maruo, Masahito Ohji.
References
1. Gilbert C. Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk
and implications for control. Early Hum Dev. 2008; 84(2):77–82. Epub 2008/02/01. https://doi.org/10.
1016/j.earlhumdev.2007.11.009 PMID: 18234457.
2. Rengstorff RH, Doughty CB. Mydriatic and cycloplegic drugs: a review of ocular and systemic complica-
tions. Am J Optom Physiol Opt. 1982; 59(2):162–77. Epub 1982/02/01. PMID: 7039329.
3. Kremer LJ, Reith DM, Medlicott N, Broadbent R. Systematic review of mydriatics used for screening of
retinopathy in premature infants. BMJ Paediatr Open. 2019; 3(1):e000448. https://doi.org/10.1136/
bmjpo-2019-000448 PMID: 31206081.
4. Mitchell A, Hall RW, Erickson SW, Yates C, Lowery S, Hendrickson H. Systemic Absorption of Cyclo-
pentolate and Adverse Events After Retinopathy of Prematurity Exams. Curr Eye Res. 2016; 41
(12):1601–7. https://doi.org/10.3109/02713683.2015.1136419 PMID: 27159349.
5. Bonthala S, Sparks JW, Musgrove KH, Berseth CL. Mydriatics slow gastric emptying in preterm infants.
J Pediatr. 2000; 137(3):327–30. Epub 2000/09/02. https://doi.org/10.1067/mpd.2000.107842 PMID:
10969255.
6. Mitchell AJ, Green A, Jeffs DA, Roberson PK. Physiologic effects of retinopathy of prematurity screen-
ing examinations. Adv Neonatal Care. 2011; 11(4):291–7. Epub 2011/11/30. https://doi.org/10.1097/
ANC.0b013e318225a332 PMID: 22123352.
7. Jiang JB, Zhang ZW, Zhang JW, Wang YL, Nie C, Luo XQ. Systemic changes and adverse effects
induced by retinopathy of prematurity screening. Int J Ophthalmol. 2016; 9(8):1148–55. https://doi.org/
10.18240/ijo.2016.08.11 PMID: 27588270.
8. Fierson WM, American Academy of Pediatrics Section on O, American Academy of O, American Asso-
ciation for Pediatric O, Strabismus, American Association of Certified O. Screening examination of pre-
mature infants for retinopathy of prematurity. Pediatrics. 2013; 131(1):189–95. https://doi.org/10.1542/
peds.2012-2996 PMID: 23277315.
9. Degirmencioglu H, Oncel MY, Calisici E, Say B, Uras N, Dilmen U. Transient ileus associated with the
use of mydriatics after screening for retinopathy of prematurity in a very low birth weight infant. J Pediatr
Ophthalmol Strabismus. 2014; 51 Online:e44–7. Epub 2014/07/09. https://doi.org/10.3928/01913913-
20140701-02 PMID: 25003832.
10. Sarici SU, Yurdakok M, Unal S. Acute gastric dilatation complicating the use of mydriatics in a preterm
newborn. Pediatr Radiol. 2001; 31(8):581–3. Epub 2001/09/12. https://doi.org/10.1007/
s002470100498 PMID: 11550771.
11. Gronlund JU, Antila KJ, Siimes AS, Metsala T, Oja R, Tuominen J, et al. Beta-adrenergic control and
inter-relationships between heart rate and blood pressure in neonatal lambs. Med Biol Eng Comput.
1989; 27(2):163–70. Epub 1989/03/01. https://doi.org/10.1007/BF02446226 PMID: 2574762.
12. Isenberg S, Everett S, Parelhoff E. A comparison of mydriatic eyedrops in low-weight infants. Ophthal-
mology. 1984; 91(3):278–9. https://doi.org/10.1016/s0161-6420(84)34303-2 PMID: 6546977.
13. Lees BJ, Cabal LA. Increased blood pressure following pupillary dilation with 2.5% phenylephrine
hydrochloride in preterm infants. Pediatrics. 1981; 68(2):231–4. PMID: 7267230.
14. Laws DE, Morton C, Weindling M, Clark D. Systemic effects of screening for retinopathy of prematurity.
Br J Ophthalmol. 1996; 80(5):425–8. Epub 1996/05/01. https://doi.org/10.1136/bjo.80.5.425 PMID:
8695564.
15. Phamonvaechavan P, Chutasmit K, Damrongrak P, Koukiatkul S, Wongkiatkajorn T, Ngerncham S.
Comparison of the effectiveness of mydriasis by two instillation methods of combined 0.75% tropica-
mide and 2.5% phenylephrine eye drop in preterm infants. J Med Assoc Thai. 2012; 95 Suppl 4:S1–7.
Epub 2012/06/16. PMID: 22696845.
PLOS ONE Adverse events after ROP screening
PLOS ONE | https://doi.org/10.1371/journal.pone.0256878 September 9, 2021 9 / 10
16. Khoo BK, Koh A, Cheong P, Ho NK. Combination cyclopentolate and phenylephrine for mydriasis in
premature infants with heavily pigmented irides. J Pediatr Ophthalmol Strabismus. 2000; 37(1):15–20.
PMID: 10714690.
17. Rosales T, Isenberg S, Leake R, Everett S. Systemic effects of mydriatics in low weight infants. J
Pediatr Ophthalmol Strabismus. 1981; 18(6):42–4. Epub 1981/11/01. PMID: 7334446.
18. Rush R, Rush S, Nicolau J, Chapman K, Naqvi M. Systemic manifestations in response to mydriasis
and physical examination during screening for retinopathy of prematurity. Retina. 2004; 24(2):242–5.
https://doi.org/10.1097/00006982-200404000-00009 PMID: 15097885.
19. Bolt B, Benz B, Koerner F, Bossi E. A Mydriatic Eye-Drop Combination Without Systemic Effects for
Premature Infants: A Prospective Double-Blind Study J Pediatr Ophthalmol Strabismus 1992; 29
(3):157–62. PMID: 1432499
PLOS ONE Adverse events after ROP screening
PLOS ONE | https://doi.org/10.1371/journal.pone.0256878 September 9, 2021 10 / 10
